Join
Live feed
·
PRReleasevia Quantisnow
Cogent Biosciences Inc. logo

Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis

ByQuantisnow·Wall Street's wire, on your screen.
COGT· Cogent Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track COGT (Cogent Biosciences Inc.) and more on Quantisnow.